SLE - Rituximab in lupus
B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled tr...
Salvato in:
| Pubblicato in: | Arthritis Res Ther |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2003
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165056/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823844/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar759 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|